Proceedings: PET Drugs-A Workshop on Inspections Management and Regulatory Considerations

Area of Science:

• Nuclear Medicine
• Radiopharmaceutical Chemistry
• Regulatory Science

Background:

• Recent advancements have led to FDA approval of new molecular imaging agents for PET.
• Continued use of PET drugs depends on compliant manufacturing facilities adhering to current good manufacturing practices (cGMP).

Purpose of the Study:

• To address regulatory considerations and inspection management for PET drug manufacturing.
• To foster collaboration between regulatory bodies and the PET drug industry.

Main Methods:

• A public workshop titled "PET Drugs: A Workshop on Inspections Management and Regulatory Considerations" was convened.
• The workshop involved cosponsorship from key organizations including the FDA, SNMMI, MIIM, WMIS, and the Coalition of PET Drug Manufacturers.
• The organizing committee comprised academic, commercial PET manufacturers, and FDA staff.

Main Results:

• The workshop facilitated discussions on critical aspects of PET drug manufacturing and regulatory compliance.
• It highlighted the importance of a sustainable network of PET manufacturing facilities.
• Key considerations for inspection management and regulatory pathways were explored.

Conclusions:

• Collaboration between the FDA and industry is crucial for ensuring the availability of PET drugs.
• Adherence to cGMP regulations is essential for maintaining the quality and safety of PET imaging agents.
• The workshop served as a platform for dialogue to support the PET drug supply chain.